Olanzapine for Chemotherapy-induced Nausea and Vomiting Prophylaxis

Efficacy and Dosage of Olanzapine for Chemotherapy-induced Nausea and Vomiting Prophylaxis in Women With Gynecologic Cancers Receiving Carboplatin-based Regimen : a Double-blind, Placebo-controlled, Randomized Crossover Trial

To investigate that olanzapine can reduced side effect about nausea and vomiting in women with gynecologic cancers receiving carboplatin-based regimen by using olanzapine and placebo

A double-blind, placebo-controlled, randomized crossover trial

Inclusion Criteria:

• Women with gynecological cancer receiving carboplatin-based chemotherapeutic regimen
• ECOG performance status 0-1
• Normal bone marrow, liver, and renal functions
• Can speak and write in Thai language

Exclusion Criteria:

• Women with nausea or vomiting prior to chemotherapeutic administration
• Pregnant women
• Women with active infection
• Women with bowel obstruction
• Women with symptomatic brain metastases
• Women who received dopamine receptor antagonists within 1 week before chemotherapeutic administration
• Women who received corticosteroid within 1 week before chemotherapeutic administration
• Women with past history of chemotherapy or radiotherapy
• Women with psychiatric disorders
• Women with poor controlled diabetes mellitus
• Women who received anticonvulsant medication
• Women with history of neuroleptic malignant syndrome
• Women with history of olanzapine allergy
• Women with history of lactose intolerance